A cost-effectiveness analysis of n-3 PUFA (Omacor®) treatment in post-MI patients

International Journal of Clinical Practice

Volumn 60, Issue 8, 2006, Pages 922-932

  Quilici, Sibilia ^a   Martin, M ^a   McGuire, A ^b   Zoellner, Y ^c  

^a i3 Innovus ^*  (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Cost effectiveness; Model; Myocardial infarction; Omacor; Prevention; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METOPROLOL; OMEGA 3 FATTY ACID; RAMIPRIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFICACY; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 33746137198     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01009.x     Document Type: Article

References (47)

1. British Heart Foundation Statistics Website. Incidence of Myocardial Infarction. URL http://www.heartstats.org [accessed on April 6 2004].
2. NHS. Cardiovascular death rates. URL http://www.nhsinherts.nhs.uk [accessed on 1 March 2005].
3. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547-57.
4. World Heart Organisation. Death Rates from CHD, Men and Women Aged 35-74, Selected Countries. URL http://www.who.org [accessed on April 6 2004].
5. Department of Health. National service framework for coronary heart disease. URL http://www.dh.gov.uk [accessed on January 1 2005].
6. Liu JL, Maniadakis N, Gray A et al. The economic burden of coronary heart disease in the UK. Heart 2002; 88: 597-603.
7. Bowker TJ, Clayton TC, Ingham J et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
8. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease. [18]. Eur Heart 1997; 10: 1569-82.
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
10. Imazio M, Forno D, Quaglia C et al. Omega-3 polyunsatured fatty acids role in postmyocardial infarction therapy. Panminerva Med 2003; 45: 99-107.
11. Lee KW, Lip GY. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM 2003; 96: 465-80.
12. GISSI-P Study Group. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-55.
13. Whelton SP, He J, Whelton PK et al. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 2004; 93: 1119-23.
14. Kris-Etherton PM, Harris WS, Appel LJ et al. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-57.
15. Nilsen DW, Albrektsen G, Landmark K et al. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001; 74: 50-6.
16. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005; 293: 1338-47.
17. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224-7.
18. Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-903.
19. Caro JJ, Ishak KJ, Migliaccio-Walle K et al. Estimating survival for cost-effectiveness analyses: A case study in atherothrombosis. Value Health 2004; 7: 627-35.
20. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
21. National Institute of Clinical Excellence. NICE: Guideline Development Methods. Chapter 8, http://www.mce.org.uk, 2004.
22. Youman P, Wilson K, Harraf F et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21 (Suppl. 1): 43-50.
23. DIN-LINK database. Doctors' independent network. URL http://www.compufile.co.uk [accessed on January 1 2005].
24. Curtis L, Netten A. Unit costs of health and social care 2004. URL http://www.pssru.ac.uk [accessed on January 1 2005].
25. EuroQSL Group. Health survey for England 1996: Chapter 5: self-reported health: Mean EuroQoL tariff by age and sex. Table 5.29. URL http://www.archive.official-documents.co.uk [accessed on October 1 2004].
26. Schleinitz MD, Weiss JP, Owens DK et al. Clopidogrel vs. aspirin for secondary prophylaxis of vascular events: A cost-effectiveness analysis. Am J Med 2004; 116: 797-806.
27. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003; 21: 191-200.
28. Health survey of England. 1996: http://www.archive-documents.co.uk.
29. Department of Health. NHS reference costs 2003 and National tariff 2004. Appendix 4. URL http://www.dh.gov.uk [accessed 1 October 2004].
30. Franzosi MG, Brunetti M, Marchioli R et al. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001; 19: 411-20.
31. National Institute for Clinical Excellence. Prophylaxis for Patients who Have Experienced a Myocardial Infarction Drug Treatment, Cardiac Rehabilitation and Dietary Manipulation. http://www.nice.org.uk, NHS, 2001.
32. Volmink JA, Newton JN, Hicks NR et al. Coronary event and case fatality rates in an English population: Results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart 1998; 80: 40-4.
33. Tavazzi L, Tognoni G, Franzosi MG et al. Rationale and design of the GISSI heart failure trial: A large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004; 6: 635-41.
34. Clinical Trial Services Unit. ASCEND trial. URL http://www.ctsu.ox.ac.uk [accessed on January 1 2005].
35. Sanmuganathan PS, Ghahramani P, Jackson PR et al. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001; 85: 265-71.
36. Rembold CM. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. J Fam Pract 1996; 42: 577-86.
37. Prosser LA, Stinnett AA, Goldman PA et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000; 132: 769-79.
38. Ganz DA, Kuntz KM, Jacobson GA et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132: 780-7.
39. Barry M, Heerey A. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland. Ir Med J 2002; 95: 133-5.
40. Scuffham PA, Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. Pharmacoeconomics 2004; 22: 525-35.
41. Phillips KA, Shlipak MG, Coxson P et al. Health and economic benefits of increased beta-blocker use following myocardial infarction. JAMA 2000; 284: 2748-54.
42. Gaziano JM, Skerrett PJ, Buring JE et al. Aspirin in the treatment and prevention of cardiovascular disease. Haemostasis 2000; 30 (Suppl. 3): 1-13.
43. McMurray JJ, McGuire A, Davie AP et al. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411-5.
44. Franzosi M, Maggioni A, Santoro E et al. Analisi costo-efficacia dell'impiego precoce di lisinopril nei pazienti con infarcto miocardico acuto: I risultati del trial GISSI-3. Pharmacoeconomics 2005; 2: 43-52.
45. Kaplan RC, Heckbert SR, Furberg CD et al. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002; 55: 654-64.
46. Hardie K, Hankey GJ, Jamrozik K et al. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004; 35: 731-5.
47. Ulf Stenestrand. RIKS-HIA 2002 Annual Report. Register for Information & Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). 25-2-2002..